Flexion Therapeutics Profit Margin

Flexion Therapeutics (FLXN) currently reports a profit margin of -100.32% as of September 2021. That compares with -153.9% in the prior-year period — up 34.8% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore Flexion Therapeutics's profit margin history and peer comparisons.

Flexion Therapeutics's profit margin increased from -153.9% to -100.32% — a 34.8% year-over-year increase (period ending September 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Flexion Therapeutics's profit margin of -100.32% is lower than the Healthcare sector average of 14.34%. That is roughly 799.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Flexion Therapeutics's current -100.32% should be judged against Healthcare norms (sector average: 14.34%) and against FLXN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -100.32%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Flexion Therapeutics, and consider following FLXN for alerts when major investors trade the stock.